Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a significant impact on quality of life. Benralizumab has shown efficacy in severe eosinophilic asthma, but there is limited evidence for CRSwNP. A prospective observational study was conducted in a tertiary hospital with six adults with severe CRSwNP, according to EPOS2020 criteria, treated for 52 weeks. All had multiple surgeries (mean 3.3) and high cumulative exposure to systemic corticosteroids. Initially, they presented a high symptom and endoscopic burden (SNOT-22: 72; NPS: 5.2). After 16 and 52 weeks, significant improvements were observed in SNOT-22 (40.3 and 28.8), NPS (4.3 and 2.7), corticosteroid use, and complete eosinophil depletion. VAS scores improved, especially in smell, rhinorrhea, and general condition. No significant adverse events occurred. These preliminary results suggest that benralizumab may be effective in CRSwNP without associated asthma, although larger controlled studies are needed.
La rinosinusitis crónica con pólipos nasales (RSCcPN) es una enfermedad inflamatoria tipo 2 con gran impacto en la calidad de vida. Benralizumab ha mostrado eficacia en asma eosinofílica grave, pero existe poca evidencia en RSCcPN. Se realizó un estudio prospectivo observacional en un hospital terciario con seis adultos con RSCcPN severa, según criterios EPOS2020, tratados durante 52 semanas. Todos tuvieron múltiples cirugías (media 3,3) y elevada exposición acumulada a corticoides sistémicos. Inicialmente presentaron alta carga sintomática y endoscópica (SNOT-22: 72; NPS: 5,2). Tras 16 y 52 semanas se observaron mejoras significativas en SNOT-22 (40,3 y 28,8), NPS (4,3 y 2,7), uso de corticoides y depleción completa de eosinófilos. Los puntajes VAS mejoraron, especialmente en olfato, rinorrea y condición general. No hubo eventos adversos relevantes. Estos resultados preliminares sugieren que benralizumab puede ser eficaz en CRSwNP sin asma asociado, aunque se requieren estudios controlados más amplios.
